Is Anyone Really Shopping For Bristol-Myers Squibb?
Bristol-Myers Squibb is on the auction block – maybe.
While there has been plenty of speculation over the last two days indicating that the big pharma could be a takeout target for some of its larger peers — including Pfizer, Johnson & Johnson, Sanofi and Novartis – a lot of that talk is based on two ideas: that Bristol-Myers is in dire straits and that activist investors are unhappy about it.
While there has been plenty of speculation over the last two days indicating that the big pharma could be a takeout target for some of its larger peers — including Pfizer, Johnson & Johnson, Sanofi and Novartis – a lot of that talk is based on two ideas: that Bristol-Myers is in dire straits and that activist investors are unhappy about it.